001360.KS
SAMSUNG PHARM. Co., LTD. [001360.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
001360.KS Stock Summary
Top 10 Correlated ETFs
001360.KS
Top 10 Correlated Stocks
001360.KS
In the News
001360.KS Financial details
Company Rating
Sell
Market Cap
159.44B
Income
-22.4B
Revenue
51.96B
Book val./share
1042.9
Cash/share
57.55
Dividend
-
Dividend %
-
Employees
240
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-5.99
Forward P/E
-
PEG
1.52
P/S
3.82
P/B
1.84
P/C
27.94
P/FCF
-6.48
Quick Ratio
-
Current Ratio
2.54
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
-301.04
EPS next Y
-
EPS next Q
-
EPS this Y
-32.86%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
3.12%
Revenue Q/Q
2.58%
EPS Q/Q
94.8%
-
-
-
-
SMA20
-8.86%
SMA50
-19.68%
SMA100
-33.29%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-29%
ROC
-0.2%
Gross Margin
46%
Oper. Margin
-33%
Profit Margin
-51%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1685.0-3784.8916
52W High
-57.51%
52W Low
-4.57%
RSI
29
Rel Volume
0.35
Avg Volume
794.43K
Volume
274.3K
Perf Week
-5.85%
Perf Month
-11.84%
Perf Quarter
-36.57%
Perf Half Y
-36.44%
-
-
-
-
Beta
0.795
-
-
Volatility
35.32%, 83.3%
Prev Close
-1.47%
Price
1608
Change
0.5%
001360.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 686.53 | 712.99 | 746.56 | 696.73 | 698.39 | |
| Net income per share | 106.06 | -941.87 | -852.31 | -496.74 | -333.53 | |
| Operating cash flow per share | -37.5 | -37.71 | -97.4 | -25.73 | -371.77 | |
| Free cash flow per share | -251.33 | -143.39 | -152.68 | -66.53 | -543.56 | |
| Cash per share | 460.69 | 428.83 | 875.75 | 752.57 | 57.55 | |
| Book value per share | 2.2K | 1.8K | 1.73K | 1.38K | 1.04K | |
| Tangible book value per share | 2.19K | 1.79K | 1.72K | 1.36K | 967.02 | |
| Share holders equity per share | 2.2K | 1.8K | 1.73K | 1.38K | 1.04K | |
| Interest debt per share | 207.83 | 446.6 | 35.72 | 28.38 | 8.99 | |
| Market cap | 272.32B | 409.58B | 362.18B | 197.51B | 152.03B | |
| Enterprise value | 280.06B | 411.28B | 338.2B | 163.53B | 148.34B | |
| P/E ratio | 39.55 | -6.42 | -5.78 | -5.34 | -6.13 | |
| Price to sales ratio | 6.11 | 8.49 | 6.6 | 3.81 | 2.93 | |
| POCF ratio | -111.87 | -160.42 | -50.56 | -103.18 | -5.5 | |
| PFCF ratio | -16.69 | -42.19 | -32.26 | -39.91 | -3.76 | |
| P/B Ratio | 1.91 | 3.36 | 2.85 | 1.93 | 1.96 | |
| PTB ratio | 1.91 | 3.36 | 2.85 | 1.93 | 1.96 | |
| EV to sales | 6.28 | 8.52 | 6.16 | 3.15 | 2.86 | |
| Enterprise value over EBITDA | -161.55 | -34.88 | -23.05 | -16.17 | -9.2 | |
| EV to operating cash flow | -115.05 | -161.08 | -47.22 | -85.43 | -5.36 | |
| EV to free cash flow | -17.17 | -42.37 | -30.12 | -33.04 | -3.67 | |
| Earnings yield | 0.03 | -0.16 | -0.17 | -0.19 | -0.16 | |
| Free cash flow yield | -0.06 | -0.02 | -0.03 | -0.03 | -0.27 | |
| Debt to equity | 0.09 | 0.23 | 0.02 | 0.02 | 0.01 | |
| Debt to assets | 0.08 | 0.16 | 0.01 | 0.02 | 0.01 | |
| Net debt to EBITDA | -4.46 | -0.14 | 1.63 | 3.36 | 0.23 | |
| Current ratio | 2.76 | 1.3 | 5.11 | 4.89 | 2.3 | |
| Interest coverage | -7.38 | -4.7 | -35.79 | -125.67 | -245.91 | |
| Income quality | -0.35 | 0.06 | 0.18 | 0.08 | 1.11 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0 | 0.01 | 0.01 | 0.01 | 0.07 | |
| Intangibles to total assets | 0 | 0 | 0.01 | 0.01 | 0.06 | |
| Capex to operating cash flow | 5.7 | 2.8 | 0.57 | 1.59 | 0.46 | |
| Capex to revenue | -0.31 | -0.15 | -0.07 | -0.06 | -0.25 | |
| Capex to depreciation | -3.29 | -1.7 | -1.27 | -1.01 | -6.68 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.29K | 6.18K | 5.76K | 3.93K | 2.8K | |
| ROIC | -0.03 | -0.1 | -0.22 | -0.19 | -0.24 | |
| Return on tangible assets | 0.04 | -0.36 | -0.43 | -0.32 | -0.28 | |
| Graham Net | 381.64 | -57.1 | 806.43 | 666.62 | 29.29 | |
| Working capital | 39.12B | 15.12B | 68.69B | 55.34B | 16.64B | |
| Tangible asset value | 142.48B | 121.22B | 126.4B | 101.39B | 71.94B | |
| Net current asset value | 35.69B | 8.5B | 67.2B | 54.25B | 13.56B | |
| Invested capital | 0.09 | 0.23 | 0.02 | 0.02 | 0.01 | |
| Average receivables | 21.89B | 21.16B | 16.74B | 9.46B | 8.05B | |
| Average payables | 5.83B | 6.29B | 5.46B | 5.03B | 5.29B | |
| Average inventory | 10.81B | 12.74B | 11.9B | 7.82B | 10.65B | |
| Days sales outstanding | 157.47 | 174.63 | 68.98 | 60.22 | 53.04 | |
| Days payables outstanding | 72.36 | 54.08 | 42.61 | 63.41 | 75.81 | |
| Days of inventory on hand | 127.69 | 127.27 | 84.91 | 67.51 | 210.38 | |
| Receivables turnover | 2.32 | 2.09 | 5.29 | 6.06 | 6.88 | |
| Payables turnover | 5.04 | 6.75 | 8.57 | 5.76 | 4.81 | |
| Inventory turnover | 2.86 | 2.87 | 4.3 | 5.41 | 1.73 | |
| ROE | 0.05 | -0.52 | -0.49 | -0.36 | -0.32 | |
| Capex per share | -213.83 | -105.68 | -55.28 | -40.79 | -171.79 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 189.75 | 177.95 | 201.35 | 157.51 | 161.58 | |
| Net income per share | -235.17 | -5.24 | -48.4 | -83.92 | -163.48 | |
| Operating cash flow per share | -9.25 | -74.51 | -118.06 | -86.12 | -93.08 | |
| Free cash flow per share | -23.44 | -79.11 | -281.94 | -91.5 | -91 | |
| Cash per share | 752.57 | 631.28 | 285.13 | 132.83 | 57.55 | |
| Book value per share | 1.38K | 1.34K | 1.29K | 1.21K | 1.04K | |
| Tangible book value per share | 1.36K | 1.33K | 1.12K | 1.03K | 967.02 | |
| Share holders equity per share | 1.38K | 1.34K | 1.29K | 1.21K | 1.04K | |
| Interest debt per share | 27.27 | 20.68 | 18.38 | 15.98 | 8.18 | |
| Market cap | 197.51B | 192.68B | 231.73B | 199B | 152.03B | |
| Enterprise value | 163.53B | 167.23B | 221.87B | 198.29B | 148.34B | |
| P/E ratio | -2.82 | -123.53 | -16.09 | -7.97 | -3.13 | |
| Price to sales ratio | 13.99 | 14.55 | 15.47 | 16.98 | 12.65 | |
| POCF ratio | -286.9 | -34.76 | -26.39 | -31.06 | -21.95 | |
| PFCF ratio | -113.28 | -32.74 | -11.05 | -29.23 | -22.46 | |
| P/B Ratio | 1.93 | 1.93 | 2.41 | 2.21 | 1.96 | |
| PTB ratio | 1.93 | 1.93 | 2.41 | 2.21 | 1.96 | |
| EV to sales | 11.58 | 12.63 | 14.81 | 16.92 | 12.34 | |
| Enterprise value over EBITDA | -41.15 | -35.18 | 27.52 | 35.11 | -31.59 | |
| EV to operating cash flow | -237.53 | -30.17 | -25.26 | -30.95 | -21.42 | |
| EV to free cash flow | -93.79 | -28.41 | -10.58 | -29.13 | -21.91 | |
| Earnings yield | -0.09 | 0 | -0.02 | -0.03 | -0.08 | |
| Free cash flow yield | -0.01 | -0.03 | -0.09 | -0.03 | -0.04 | |
| Debt to equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 8.55 | 5.35 | -1.22 | -0.13 | 0.78 | |
| Current ratio | 4.89 | 3.86 | 2.75 | 2.54 | 2.3 | |
| Interest coverage | -180.87 | -224.83 | -210.88 | -202.3 | -387.17 | |
| Income quality | 0.06 | 1.97 | 2.44 | 1.03 | 0.57 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.79 | 0.77 | 0.02 | |
| Research and developement to revenue | 0 | 0.02 | 0.02 | 0.05 | 0.07 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.12 | 0.13 | 0.06 | |
| Capex to operating cash flow | 1.53 | 0.06 | 1.39 | 0.06 | -0.02 | |
| Capex to revenue | -0.07 | -0.03 | -0.81 | -0.03 | 0.01 | |
| Capex to depreciation | -1.31 | -0.77 | -25.65 | -0.8 | 0.31 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.7K | 397.72 | 1.19K | 1.51K | 1.96K | |
| ROIC | -0.08 | -0.01 | -0.04 | -0.04 | -0.07 | |
| Return on tangible assets | -0.15 | 0 | -0.04 | -0.07 | -0.14 | |
| Graham Net | 666.62 | 541.19 | 248.04 | 130.56 | 29.29 | |
| Working capital | 55.34B | 47.39B | 27.13B | 19.64B | 16.64B | |
| Tangible asset value | 101.39B | 98.58B | 83.02B | 76.77B | 71.94B | |
| Net current asset value | 54.25B | 46.59B | 26.48B | 18.94B | 13.56B | |
| Invested capital | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 7.93B | 8.62B | 9.68B | 9.4B | 7.84B | |
| Average payables | 4.44B | 5.62B | 6.54B | 5.91B | 5.55B | |
| Average inventory | 6.58B | 6.67B | 9.51B | 12.56B | 15.33B | |
| Days sales outstanding | 54.52 | 59.05 | 64.16 | 62.4 | 56.53 | |
| Days payables outstanding | 50.24 | 75.31 | 85.6 | 77.75 | 65.47 | |
| Days of inventory on hand | 53.5 | 96.25 | 139.41 | 213.57 | 181.7 | |
| Receivables turnover | 1.65 | 1.52 | 1.4 | 1.44 | 1.59 | |
| Payables turnover | 1.79 | 1.19 | 1.05 | 1.16 | 1.37 | |
| Inventory turnover | 1.68 | 0.94 | 0.65 | 0.42 | 0.5 | |
| ROE | -0.17 | 0 | -0.04 | -0.07 | -0.16 | |
| Capex per share | -14.18 | -4.6 | -163.88 | -5.38 | 2.08 |
001360.KS Frequently Asked Questions
What is SAMSUNG PHARM. Co., LTD. stock symbol ?
SAMSUNG PHARM. Co., LTD. is a KR stock and trading under the symbol 001360.KS
What is SAMSUNG PHARM. Co., LTD. stock quote today ?
SAMSUNG PHARM. Co., LTD. stock price is $1608 today.
Is SAMSUNG PHARM. Co., LTD. stock public?
Yes, SAMSUNG PHARM. Co., LTD. is a publicly traded company.
Company Profile
- Volume Average 794.43K
- Market Capitalization 159.44B
- Employee 240
- CEO Mr. Won-Kyu Kim
- Headquarters Hwaseong-si,KR
- IPO Date 2000-01-04
-
Website
https://www.sspharm.co.kr 
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, and others, as well as vitamins and energy drinks, and functional foods. The company was founded in 1929 and is based in Hwaseong-si, South Korea.
